|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.04.26 - 00:03
|
MESA LABS DECLARES QUARTERLY DIVIDEND (GlobeNewswire EN)
|
|
|
LAKEWOOD, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026....
|
|
|
03.04.26 - 00:03
|
Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026 (GlobeNewswire EN)
|
|
|
SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific)....
|
|
|
02.04.26 - 23:48
|
Conavi Medical Announces Results from Its Annual General Meeting of Shareholders (GlobeNewswire EN)
|
|
|
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2026 (the “Meeting”), as well as the adoption of amendments to the Company's Stock Option Plan....
|
|
|
02.04.26 - 23:48
|
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
02.04.26 - 23:30
|
Mattr Announces Closing of Credit Facility Extension (GlobeNewswire EN)
|
|
|
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced that it has successfully closed on an amendment to its credit facility with The Toronto-Dominion Bank and National Bank of Canada as co-lead arrangers and Royal Bank of Canada, JP Morgan Chase Bank, Export Development Canada and ATB Financial as lenders to extend the US$300 million senior secured revolving facility until October 2030....
|
|
|
02.04.26 - 23:09
|
Diversified Royalty Corp. Announces April 2026 Cash Dividend (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.02375 per common share for the period of April 1, 2026 to April 30, 2026, which is equal to $0.285 per common share on an annualized basis. The dividend will be paid on April 30, 2026 to shareholders of record as of the close of business on April 15, 2026....
|
|